REN and Hypertension: However, considering the high prevalence of renin–angiotensin system inhibitor (RASi) usage for hypertension among LTCF residents [15], cautious administration is warranted, as concurrent trimethoprim–sulfamethoxazole and RASi use has been associated with an increased risk of sudden mortality [16].